Market capitalization | $202.73m |
Enterprise Value | $36.47m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.26 |
P/S ratio (TTM) P/S ratio | 1.43 |
P/B ratio (TTM) P/B ratio | 1.69 |
Revenue growth (TTM) Revenue growth | 16.68% |
Revenue (TTM) Revenue | $141.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a MacroGenics, Inc. forecast:
11 Analysts have issued a MacroGenics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 141 141 |
17%
17%
|
|
Gross Profit | 127 127 |
27%
27%
|
|
EBITDA | -100 -100 |
4%
4%
|
EBIT (Operating Income) EBIT | -107 -107 |
0%
0%
|
Net Profit | -98 -98 |
296%
296%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Scott Koenig |
Employees | 339 |
Founded | 2000 |
Website | www.macrogenics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.